ECM
MBRX icon

ETrade Capital Management’s Moleculin Biotech MBRX Stock Holding History

ETrade Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$47K Buy
+26
New +$55.3K ﹤0.01% 862

Other funds holding MBRX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ETrade Capital Management's MBRX Position: Q3 2020 in Review

ETrade Capital Management opened a new position in Moleculin Biotech (MBRX) in Q3 2020: 26 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #862 among its holdings.

18 funds tracked by Wall St. Rank hold MBRX as of Q3 2020.

  • ETrade Capital Management held 26 shares of Moleculin Biotech worth $47K as of Q3 2020.
  • Moleculin Biotech was a new ETrade Capital Management position in Q3 2020.
  • Moleculin Biotech made up ﹤0.01% of ETrade Capital Management's portfolio in Q3 2020, its #862 holding.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.